These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 2006142

  • 1. Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line.
    Bryant ML, Ratner L, Duronio RJ, Kishore NS, Devadas B, Adams SP, Gordon JI.
    Proc Natl Acad Sci U S A; 1991 Mar 15; 88(6):2055-9. PubMed ID: 2006142
    [Abstract] [Full Text] [Related]

  • 2. Protein N-myristoylation in Escherichia coli: reconstitution of a eukaryotic protein modification in bacteria.
    Duronio RJ, Jackson-Machelski E, Heuckeroth RO, Olins PO, Devine CS, Yonemoto W, Slice LW, Taylor SS, Gordon JI.
    Proc Natl Acad Sci U S A; 1990 Feb 15; 87(4):1506-10. PubMed ID: 2406721
    [Abstract] [Full Text] [Related]

  • 3. Substrate specificity of Saccharomyces cerevisiae myristoyl-CoA: protein N-myristoyltransferase. Analysis of fatty acid analogs containing carbonyl groups, nitrogen heteroatoms, and nitrogen heterocycles in an in vitro enzyme assay and subsequent identification of inhibitors of human immunodeficiency virus I replication.
    Devadas B, Lu T, Katoh A, Kishore NS, Wade AC, Mehta PP, Rudnick DA, Bryant ML, Adams SP, Li Q.
    J Biol Chem; 1992 Apr 15; 267(11):7224-39. PubMed ID: 1559967
    [Abstract] [Full Text] [Related]

  • 4. Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid.
    Bryant ML, Heuckeroth RO, Kimata JT, Ratner L, Gordon JI.
    Proc Natl Acad Sci U S A; 1989 Nov 15; 86(22):8655-9. PubMed ID: 2813417
    [Abstract] [Full Text] [Related]

  • 5. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
    Bryant M, Ratner L.
    Proc Natl Acad Sci U S A; 1990 Jan 15; 87(2):523-7. PubMed ID: 2405382
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens.
    Schwendener RA, Gowland P, Horber DH, Zahner R, Schertler A, Schott H.
    Antiviral Res; 1994 May 15; 24(1):79-93. PubMed ID: 7944315
    [Abstract] [Full Text] [Related]

  • 10. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
    Park J, Morrow CD.
    Virology; 1993 Jun 15; 194(2):843-50. PubMed ID: 8503189
    [Abstract] [Full Text] [Related]

  • 11. The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.
    Dorfman T, Göttlinger HG.
    J Virol; 1996 Sep 15; 70(9):5751-7. PubMed ID: 8709190
    [Abstract] [Full Text] [Related]

  • 12. Binding of human immunodeficiency virus type 1 (HIV-1) RNA to recombinant HIV-1 gag polyprotein.
    Luban J, Goff SP.
    J Virol; 1991 Jun 15; 65(6):3203-12. PubMed ID: 2033671
    [Abstract] [Full Text] [Related]

  • 13. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
    Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW.
    Proc Natl Acad Sci U S A; 2000 Nov 21; 97(24):13057-62. PubMed ID: 11087859
    [Abstract] [Full Text] [Related]

  • 14. Heme inhibits human immunodeficiency virus 1 replication in cell cultures and enhances the antiviral effect of zidovudine.
    Levere RD, Gong YF, Kappas A, Bucher DJ, Wormser GP, Abraham NG.
    Proc Natl Acad Sci U S A; 1991 Mar 01; 88(5):1756-9. PubMed ID: 2000384
    [Abstract] [Full Text] [Related]

  • 15. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
    Lambert DM, Bartus H, Fernandez AV, Bratby-Anders C, Leary JJ, Dreyer GB, Metcalf BW, Petteway SR.
    Antiviral Res; 1993 Aug 01; 21(4):327-42. PubMed ID: 7692816
    [Abstract] [Full Text] [Related]

  • 16. Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains.
    Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, Wolfe AD, Garcia GE, Doctor BP, Burke DS, Gordon RK.
    Proc Natl Acad Sci U S A; 1995 Jan 03; 92(1):215-9. PubMed ID: 7816820
    [Abstract] [Full Text] [Related]

  • 17. The HIV-1 Gag precursor Pr55gag synthesized in yeast is myristoylated and targeted to the plasma membrane.
    Jacobs E, Gheysen D, Thines D, Francotte M, de Wilde M.
    Gene; 1989 Jun 30; 79(1):71-81. PubMed ID: 2673935
    [Abstract] [Full Text] [Related]

  • 18. Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain.
    Platt EJ, Haffar OK.
    Proc Natl Acad Sci U S A; 1994 May 10; 91(10):4594-8. PubMed ID: 8183954
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist.
    Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ.
    Science; 1991 Dec 20; 254(5039):1799-802. PubMed ID: 1763331
    [Abstract] [Full Text] [Related]

  • 20. Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells.
    Chazal N, Carrière C, Gay B, Boulanger P.
    J Virol; 1994 Jan 20; 68(1):111-22. PubMed ID: 8254720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.